nct_id: NCT06057402
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-09-28'
study_start_date: '2023-10-03'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Elranatamab'
long_title: 'ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS
  WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES'
last_updated: '2025-11-18'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE4
principal_investigator: NA
principal_investigator_institution: Pfizer
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 80
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Participants must agree to follow the reproductive criteria as outlined in the
  protocol'
- '* Participants have completed a qualifying Parent Study, were still receiving elranatamab
  when the Parent Study terminated or completed, and are deriving clinical benefit
  from elranatamab (as determined by the investigator).'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Any medical or psychiatric condition including recent (within the past
  year) or active suicidal ideation/behavior or laboratory abnormality that may increase
  the risk of study participation or, in the investigator's judgment, make the participant
  inappropriate for the study.
- Exclude - * Participants not previously enrolled or who have discontinued study
  treatment in a Parent Study are ineligible for participation in this study.
short_title: Elranatamab Post Trial Access Study for Participants With Multiple Myeloma
  (MM)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Pfizer
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a post-trial access (PTA) open-label, single-arm study in Multiple
  Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy
  in the Pfizer-sponsored elranatamab Parent Studies.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Elranatamab
      arm_internal_id: 0
      arm_description: Elranatamab is a heterodimeric humanized full length bispecific
        IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Elranatamab'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        oncotree_primary_diagnosis: Lymphoid Neoplasm
